Israel Englander Pro Qr Therapeutics N.V. Transaction History

Millennium Management LLC

$192 Billion
Q4 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Millennium Management LLC holds 2,827,280 shares of PRQR stock, worth $6.84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,827,280

Previous 143,929 1864.36%

Holding current value

$6.84 Million

Previous $261,000 2857.09%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.81 - $4.49 $4.86 Million - $12 Million	2,683,351 Added 1864.36%	2,827,280 $7.72 Million
Q3 2024 Nov 14, 2024	SELL	$1.64 - $2.24 $7,261 - $9,918	-4,428 Reduced 2.98%	143,929 $261,000
Q2 2024 Aug 14, 2024	SELL	$1.65 - $2.39 $298,042 - $431,710	-180,632 Reduced 54.91%	148,357 $246,000
Q1 2024 May 15, 2024	SELL	$1.89 - $2.85 $226,937 - $342,208	-120,073 Reduced 26.74%	328,989 $753,000
Q4 2023 Feb 14, 2024	SELL	$1.15 - $2.21 $186,988 - $359,343	-162,599 Reduced 26.58%	449,062 $889,000
Q2 2023 Aug 14, 2023	SELL	$1.62 - $2.32 $1.13 Million - $1.62 Million	-698,745 Reduced 53.32%	611,661 $990,000
Q1 2023 May 15, 2023	BUY	$1.99 - $3.66 $2.23 Million - $4.1 Million	1,121,490 Added 593.64%	1,310,406 $2.79 Million
Q4 2022 Feb 14, 2023	BUY	$0.8 - $3.7 $151,132 - $698,989	188,916 New	188,916 $699,000
Q2 2022 Aug 15, 2022	SELL	$0.56 - $1.0 $332,780 - $594,251	-594,251 Reduced 89.98%	66,157 $51,000
Q1 2022 May 16, 2022	BUY	$0.9 - $8.39 $365,345 - $3.41 Million	405,939 Added 159.52%	660,408 $598,000
Q4 2021 Feb 14, 2022	SELL	$6.58 - $8.44 $546,370 - $700,815	-83,035 Reduced 24.6%	254,469 $2.04 Million
Q3 2021 Nov 15, 2021	BUY	$5.16 - $8.47 $1.68 Million - $2.76 Million	325,364 Added 2680.1%	337,504 $2.83 Million
Q2 2021 Aug 16, 2021	SELL	$5.75 - $7.59 $142,007 - $187,450	-24,697 Reduced 67.04%	12,140 $82,000
Q1 2021 May 17, 2021	SELL	$4.14 - $9.22 $600,490 - $1.34 Million	-145,046 Reduced 79.75%	36,837 $243,000
Q4 2020 Feb 16, 2021	BUY	$3.58 - $4.85 $651,141 - $882,132	181,883 New	181,883 $764,000
Q2 2020 Aug 14, 2020	SELL	$4.5 - $6.53 $277,717 - $402,998	-61,715 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$5.25 - $9.9 $1.48 Million - $2.79 Million	-281,431 Reduced 82.01%	61,715 $339,000
Q4 2019 Feb 14, 2020	BUY	$5.84 - $10.51 $704,111 - $1.27 Million	120,567 Added 54.17%	343,146 $3.4 Million
Q3 2019 Nov 14, 2019	SELL	$5.76 - $9.44 $555,805 - $910,903	-96,494 Reduced 30.24%	222,579 $1.28 Million
Q2 2019 Aug 15, 2019	BUY	$9.1 - $15.55 $1.22 Million - $2.09 Million	134,607 Added 72.97%	319,073 $2.9 Million
Q1 2019 May 14, 2019	BUY	$12.5 - $18.48 $1.17 Million - $1.74 Million	93,968 Added 103.83%	184,466 $2.56 Million
Q4 2018 Feb 14, 2019	BUY	$15.25 - $22.4 $1.38 Million - $2.03 Million	90,498 New	90,498 $1.43 Million
Q3 2018 Nov 14, 2018	SELL	$6.45 - $21.6 $1.26 Million - $4.22 Million	-195,352 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.95 - $7.45 $576,288 - $1.46 Million	195,352 New	195,352 $1.43 Million

Others Institutions Holding PRQR

# of Institutions

Shares Held

40M

Call Options Held

10.7K

Put Options Held

24.1K

View Full List

About ProQR Therapeutics N.V.

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $173M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

More about PRQR

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account